CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Estradiol patchWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)


Name (Synonyms) Correlation
drug2989 risankizumab Wiki 1.00
drug2953 placebo for risankizumab Wiki 1.00

Correlated MeSH Terms (3)


Name (Synonyms) Correlation
D014456 Ulcer NIH 0.41
D003092 Colitis NIH 0.41
D003093 Colitis, Ulcerative NIH 0.41

Correlated HPO Terms (2)


Name (Synonyms) Correlation
HP:0002583 Colitis HPO 0.41
HP:0100279 Ulcerative colitis HPO 0.41

There is one clinical trial.

Clinical Trials


1 Phase II Clinical Trial of Estradiol to Reduce Severity of COVID19 Infection in COVID19+ and Presumptive COVID19+ Patients

The purpose of this study is to find out if estrogen, a female sex hormone, given as a patch placed on skin of COVID19 positive or presumptive positive patients for 7 days can reduce the severity of COVID19 symptoms compared to regular care. This study has two study groups. One group will receive the study drug, a single-use Climara 25cm2 estrogen patch. The other group will receive standard of care. Participants will be asked questions about their symptoms for up 6 times in up to 45 days.

NCT04359329 COVID Drug: Estradiol patch

Primary Outcomes

Description: Admission to hospital due to COVID-19 symptoms

Measure: Rate of Hospitalization

Time: 30 days

Description: Occurrence of admission to ICU due to COVID-19 symptoms

Measure: Rate of Transfer to Intensive Care Unit

Time: 30 days

Description: Occurrence of intubation

Measure: Rate of Intubation

Time: 30 days

Description: Occurrence of death from COVID-19

Measure: Rate of Death

Time: 30 days


No related HPO nodes (Using clinical trials)